|CCL 18.03.06 Post Doc - De novo molecular design using Deep Learning Gothenburg, Sweden|
From: jobs at ccl.net (do not send your application there!!!)
To: jobs at ccl.net
Date: Tue Mar 6 10:55:54 2018
Subject: 18.03.06 Post Doc - De novo molecular design using Deep Learning Gothenburg, Sweden
Post Doc - De novo molecular design using Deep Learning Gothenburg, Sweden
We're currently looking for talented scientists to join our innovative academic-style Postdoc. From our centre https://www.astrazeneca.com/our-science/gothenburg.html you'll be in a global pharmaceutical environment, contributing to live projects right from the start. You'll take part in a comprehensive training programme, including a focus on drug discovery and development, given access to our existing Postdoctoral research, and encouraged to pursue your own independent research in cutting edge laboratories. It's a newly expanding programme spanning a range of therapeutic areas across a wide range of disciplines.
What's more, you'll have the support of a leading academic advisor, who'll provide you with the guidance and knowledge you need to develop your career. This is an exciting area that hasn't been explored to its full potential, making this an opportunity to make a real difference to the future of medical science.
About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines for some of the world's most serious diseases. But we're more than one of the world's leading pharmaceutical companies. At AstraZeneca, we're proud to have a unique workplace culture that inspires innovation and collaboration. Here, employees are empowered to express diverse perspectives - and are made to feel valued, energised and rewarded for their ideas and creativity.
During the last year it has been shown that Recurrent Neural Networks can very successfully be used in molecular de novo design. Together with chemistry automation, the method has the potential to make a step-change in drug discovery productivity. You will be working on the development of innovative de novo molecule design methodologies utilizing state-of-the-art artificial intelligent technologies. The developed methods will be applied on in-house drug discovery projects to show impact on the drug discovery process as well as published in high impact journals.
The Post Doc Opportunity, Accountabilities and Responsibilities:
Skills and Capabilities required:
This is a 3 year programme. 2 years will be a Fixed Term Contract, with a 1 year extension which will be merit based. The role will be based at Gothenburg with a competitive salary on offer
To apply for this position, please click the apply link below.
Advert opening date – 5th March 2018
Advert closing date – 13th May 2018
AstraZeneca welcomes applications from all sections of the community.
AstraZeneca is an equal opportunity employer. AstraZeneca will consider all qualified applicants for employment without discrimination on grounds of disability, sex or sexual orientation, pregnancy or maternity leave status, race or national or ethnic origin, age, religion or belief, gender identity or re-assignment, marital or civil partnership status, protected veteran status (if applicable) or any other characteristic protected by law.
If you share our passion for scientific excellence, find out more at; https://careers.astrazeneca.com/students/programmes/post-doctoral-programmes Or apply to this role, here: https://job-search.astrazeneca.com/job/gothenburg/post-doc-fellow-de-novo-molecular-design-using-deep-learning/7684/7417172NOTE THAT E-MAIL ADDRESSES HAVE BEEN MODIFIED!!!
All @ signs were changed to ~!~ to fight spam. Before you send e-mail, you need to change ~!~ to @
For example: change joe~!~big123comp.com to email@example.com
Please let your prospective employer know that you learned about the job from the Computational Chemistry List Job Listing at http://www.ccl.net/jobs.
|Modified: Wed Mar 7 16:02:33 2018 GMT|
|Page accessed 1812 times since Tue Mar 6 16:02:08 2018 GMT|